Technology evaluation: AAV factor IX gene therapy, Avigen Inc.

Article Details

Citation

Copy to clipboard

Fabb SA, Dickson JG

Technology evaluation: AAV factor IX gene therapy, Avigen Inc.

Curr Opin Mol Ther. 2000 Oct;2(5):601-6.

PubMed ID

11249763 [ View in PubMed

]

Abstract

Avigen has developed a recombinant adeno-associated viral vector expressing human blood-coagulation Factor IX (F.IX) for the potential treatment of hemophilia B. In a phase I clinical trial being conducted at The Children's Hospital of Philadelphia and Stanford University Medical Center, the vector, AAV-CMV-hF.IX (Coagulin-B), was injected at a low dose into three patients with severe hemophilia B. No evidence of toxicity, germline transmission of vector sequences, or formation of inhibitory antibodies against F.IX was observed, and in two of the three patients there was an indication of a modest clinical response.

DrugBank Data that Cites this Article

Drugs

Coagulin-B